Virus Or Bacteriophage Patents (Class 424/93.6)
-
Patent number: 9650272Abstract: There is provided a safe, natural, environmentally sound means of controlling bacterial contamination, corrosion, and souring of oil and gas wells and reservoirs that result from bacteria-contaminated water in a well. In one aspect it is a process for remediation of souring of petroleum reservoirs and coalbeds by adding to the water used in flooding and “fracing” operations an effective amount of virulent (non-lysogenic) bacteriophages (phages) specific for problematic target bacteria. The invention also provides a means for combating loss of effectiveness of bacterial control by staging bacteriophage production and application to control dominant and sub-dominant target bacteria in a community of target bacteria.Type: GrantFiled: October 22, 2013Date of Patent: May 16, 2017Assignee: DOW GLOBAL TECHNOLOGIES LLCInventors: Elizabeth J. Summer, Mei Liu, Neil S. Summer, Douglas Baldwin
-
Patent number: 9603909Abstract: The present invention relates to a composition for improving the stability of bacteriophage originated lysin proteins greatly even when the composition contains the bacteriophage originated lysin proteins at a high concentration. More precisely, the present invention relates to a method and a composition for improving significantly the stability of SAL-1 or LysK, the bacteriophage originated lysin protein, included at a high concentration in the composition.Type: GrantFiled: May 29, 2012Date of Patent: March 28, 2017Assignee: Intron Biotechnology, Inc.Inventors: Seong Jun Yoon, Soo Youn Jun, Gi Mo Jung, Sang Hyeon Kang
-
Patent number: 9540420Abstract: A mucosal vaccine producing an antigen-specific mucosal IgA and a blood IgG in the levels capable of exerting an effective immune induction and an infection-preventing effect, which comprises: (a) an AD vehicle consisting of a synthetic peptide and a lipid(s), wherein the synthetic peptide consisting of the amino acid sequence KnLm (wherein n is 4 to 8 and m is 11 to 20); (b) a carboxylvinyl polymer; and, (c) an antigenic protein, in an amount incapable of producing a sufficient mucosal IgA and blood IgG for exerting an effective immune induction and an infection-preventing effect when used by itself. The mucosal vaccine of the invention has an antibody producing ability which is more potent than those of mucosal vaccines of the prior art, and as a result it can exert an excellent effect even with an extremely small amount of an antigen.Type: GrantFiled: March 1, 2011Date of Patent: January 10, 2017Assignee: TOKUSHIMA UNIVERSITYInventors: Hiroshi Kido, Dai Mizuno
-
Patent number: 9534207Abstract: The present invention is related to improved modified live PRRS vaccines containing new PRRSV European strains of PRRSV and methods of use and manufacture of such vaccines.Type: GrantFiled: May 19, 2014Date of Patent: January 3, 2017Assignee: Boehringer Ingelheim Vetmedica GmbHInventors: Kim Burgard, Jeremy Kroll, Sarah M. Layton, Volker Ohlinger, Francois-Xavier Orveillon, Stefan Pesch, Michael Dennis Piontkowski, Michael B. Roof, Philip Utley, Eric Martin Vaughn
-
Patent number: 9493564Abstract: This disclosure provides a multi-specific fusion protein composed of a CD86 antagonist binding domain and another binding domain that is an IL-10 agonist, an HLA-G agonist, an HGF agonist, an IL-35 agonist, a PD-1 agonist, a BTLA agonist, a LIGHT antagonist, a GITRL antagonist or a CD40 antagonist. The multi-specific fusion protein may also include an intervening domain that separates the other domains. This disclosure also provides polynucleotides encoding the multi-specific fusion proteins, compositions of the fusion proteins, and methods of using the multi-specific fusion proteins and compositions.Type: GrantFiled: October 2, 2009Date of Patent: November 15, 2016Assignee: APTEVO RESEARCH AND DEVELOPMENT LLCInventors: Peter Armstrong Thompson, Peter Robert Baum, Philip Tan, John W. Blankenship, Sateesh Kumar Natarajan
-
Patent number: 9463240Abstract: An improved method for the manufacture of an oil-in-water emulsion comprises using a microfluidization device whose interaction chamber comprises a plurality of Z-type channels upstream of a back pressure chamber.Type: GrantFiled: July 11, 2014Date of Patent: October 11, 2016Assignee: NOVARTIS AGInventors: Harald Rueckl, Hanno Scheffczik
-
Patent number: 9457132Abstract: Medical devices that are resistant to biofilm development and methods of the manufacture of biofilm resistant medical devices are provided. One or more bacteriophages are tethered to the surface of a medical device or a hydrogei-type coating on the surface of the device by covalent bonding while maintaining bacteriophage infective or lytic activity. The presence of the bacteriophages on a medical device, such as an indwelling medical device, prevents biofilm formation or reduces existing biofilm formation on the surface of the device when in use. These devices address the long felt need for biofilm resistant devices that increase safety and reduce complications normally associated with prior indwelling or other medical devices.Type: GrantFiled: June 28, 2012Date of Patent: October 4, 2016Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Rodney Martin Donlan, Susan Marie Lehman, Andres J. Garcia
-
Patent number: 9439436Abstract: Disclosure is provided for methods of preventing, removing or inhibiting microbial biofilm formation or microbial infection in a plant or plant part thereof, including applying thereto a treatment effective amount of an aryl carbamate as described herein, or an agriculturally acceptable salt thereof. Methods of enhancing a microbicide (e.g., including a copper, antibiotic, bacteriophage, etc.) and/or plant defense activator are also provided, including applying an active compound as described herein. Compositions comprising an aryl carbamate compound as described herein in an agriculturally acceptable carrier are also provided, and in some embodiments the compositions further include a microbicide (e.g., including copper, antibiotic, bacteriophage, etc.) and/or a plant defense activator.Type: GrantFiled: July 30, 2015Date of Patent: September 13, 2016Assignee: North Carolina State UniversityInventors: Christian Melander, Steven A. Rogers
-
Patent number: 9388427Abstract: A method for treating a renal disease in a subject is disclosed. The method includes administering into a kidney of the subject with an effective amount of a gutless adenoviral vector containing a polynucleotide encoding a therapeutic agent. The gutless adenoviral vector contains the nucleotide sequence of SEQ ID NO:13 or SEQ ID NO:15 and expresses the therapeutic agent in a kidney tissue of the subject.Type: GrantFiled: January 26, 2009Date of Patent: July 12, 2016Assignee: BIOVEC, LLCInventors: Lakshman R. Sehgal, Jonathan Wong
-
Patent number: 9388453Abstract: Methods and systems are provided for packaging reporter nucleic acid molecules into non-replicative transduction particles for use as reporter molecules. The non-replicative transduction particles can be constructed from viruses and use viral transduction and replication systems. The reporter nucleic acid molecules include a reporter gene, such as a reporter molecule or selectable marker, for detecting target genes or cells. Methods and systems are provided for detection of cells and target nucleic acid molecules using the non-replicative transduction particles as reporter molecules.Type: GrantFiled: November 21, 2014Date of Patent: July 12, 2016Assignee: GENEWEAVE BIOSCIENCES, INC.Inventor: Diego Ariel Rey
-
Patent number: 9382298Abstract: The invention relates to a polypeptide, a corresponding nucleic acid molecule, a construct and/or vector and/or cell comprising such nucleic acid molecule and/or a composition comprising said polypeptide, nucleic acid molecule, construct, vector and/or cell. The invention further relates to such composition for medical use, preferably for use in treating an infectious disease. Furthermore, the invention relates to the use of said polypeptide, nucleic acid molecule, construct, vector, cell and/or composition as an antimicrobial, preferably as a food additive or disinfectant, or for detecting bacteria, preferably in a diagnostic application.Type: GrantFiled: May 4, 2011Date of Patent: July 5, 2016Assignee: Micreos Human Health B.V.Inventors: Martin Johannes Loessner, Fritz Eichenseher
-
Patent number: 9289456Abstract: In the instant invention, simvastatin (Sim) is used to modulate Vesicular Stomatitis Virus (VSV) infection at the level of viral replication for treatment of cancer. Both lipid-lowering and pleiotropic cellular effects of simvastatin are exploited in this modulation. Simvastatin upregulates the expression of Rae1 and Nup98, therefore altering normal cellular mRNA distribution and reverting VSV's mRNA export block. Furthermore, simvastatin causes redistribution of Flotillin-1, which affects VSV replication/budding. Simvastatin is further used as a neoadjuvant for the selective modulatory control of live VSV oncolytic therapy.Type: GrantFiled: November 22, 2011Date of Patent: March 22, 2016Assignee: Nova Southeastern UniversityInventors: Paula A. Faria-Waziry, Luigi X. Cubeddu, Ana Maria Castejon
-
Patent number: 9284550Abstract: Provided is a single-stranded nucleic acid aptamer specifically binding to Klebsiella pneumoniae, and a method for detecting Klebsiella pneumoniae by using the same. The aptamer of the present disclosure, and a method, a composition, a kit or a sensor of using the same may be used to specifically detect Klebsiella pneumoniae present in an aqueous environment, foods, and medical samples and also be applied in fields such as sanitary conditions of foods and medical diagnosis.Type: GrantFiled: July 30, 2014Date of Patent: March 15, 2016Assignee: Korea Institute of Science and TechnologyInventors: Byoung Chan Kim, Yeon Seok Kim, Jin Yang Chung, Jong Soo Jurng, Min Young Song
-
Patent number: 9278127Abstract: The present invention relates to monovalent influenza vaccine formulations and vaccination regimes for immunizing against influenza disease, their use in medicine, in particular their use in augmenting immune responses to various antigens, and to methods of preparation. In particular, the invention relates to monovalent influenza immunogenic compositions comprising an influenza antigen or antigenic preparation thereof from an influenza virus strain being associated with a pandemic outbreak or having the potential to be associated with a pandemic outbreak, in combination with an oil-in-water emulsion adjuvant comprising a metabolizable oil, a sterol and/or a tocopherol such as alpha tocopherol, and an emulsifying agent.Type: GrantFiled: June 17, 2011Date of Patent: March 8, 2016Assignee: GLAXOSMITHKLINE BIOLOGICALS, SAInventors: Emmanuel Jules Hanon, Jean Stephenne
-
Patent number: 9193956Abstract: The present disclosure provides adeno-associated virus (AAV) virions with altered capsid protein, where the AAV virions exhibit greater infectivity of retinal cells, when administered via intravitreal injection, compared to wild-type AAV. The present disclosure further provides methods of delivering a gene product to a retinal cell in an individual, and methods of treating ocular disease.Type: GrantFiled: April 20, 2012Date of Patent: November 24, 2015Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: David V. Schaffer, Ryan R. Klimczak, James T. Koerber, John G. Flannery, Deniz Dalkara Mourot, Meike Visel, Leah C. T. Byrne
-
Patent number: 9180150Abstract: A poxvirus comprising a defective F2L gene and compositions comprising such poxvirus are useful for therapeutic purposes, and more particularly for the treatment of cancer.Type: GrantFiled: November 17, 2008Date of Patent: November 10, 2015Assignee: Transgene S.A.Inventors: Philippe Erbs, Johann Foloppe
-
Patent number: 9180151Abstract: Embodiments of the invention are directed methods that include a thymidine kinase deficient vaccinia virus. The methods include evaluating a tumor for reperfusion after treatment with vaccinia virus and administering an anti-angiogenic agent if reperfusion is detected.Type: GrantFiled: May 8, 2014Date of Patent: November 10, 2015Assignee: SillaJen Biotherapeutics, Inc.Inventors: David Kirn, Caroline Breitbach
-
Patent number: 9175047Abstract: Peptidomimetic macrocycles and methods of using such macrocycles for the treatment of viral disease are described.Type: GrantFiled: January 14, 2010Date of Patent: November 3, 2015Assignee: Aileron Therapeutics, Inc.Inventors: Huw M. Nash, David Allen Annis
-
Patent number: 9096845Abstract: A method of preserving organisms in viable form, the method comprising: suspending organisms in a solution of electrospinnable polymer; drawing droplets of said solution through a spinneret; applying an electrostatic field to said droplets under electrospinning conditions; so as to form fibers having a diameter no greater than about 5 ?m within which distinct organisms are encapsulated in viable form.Type: GrantFiled: August 29, 2007Date of Patent: August 4, 2015Assignee: Technion Research & Development Foundation LimitedInventors: Jonathan Charles Kuhn, Eyal Zussman
-
Patent number: 9085777Abstract: The present invention includes a method of generating a mutant Herpes Simplex Virus (HSV). In one embodiment, the generated HSV genome includes nucleic acid encoding a nucleic acid sequence of interest. In one step, a nucleic acid vector is provided which includes a nucleic acid encoding first and second site specific recombination sequences and a nucleic acid encoding a nucleic acid sequence of interest between said site specific recombination sequences an HSV is provided, the genome of which comprises third and fourth site specific recombination sequences In another step, the nucleic acid vector and HSV are contacted together with one or more recombinase enzymes capable of catalyzing site specific recombination between the site specific recombination sequences of said nucleic acid vector and said HSV. Another step includes identifying HSV containing the nucleic acid sequence of interest. In some embodiments, the methods are conducted in a cell-free system.Type: GrantFiled: May 4, 2007Date of Patent: July 21, 2015Assignee: Virttu Biologics LimitedInventor: Joe Conner
-
Patent number: 9060974Abstract: The present invention is within the field of oncolytic virotherapy. Oncolytic virotherapy is a strategy using viruses, naturally occurring or genetically modified, to selectively target and destroy tumor cells while leaving surrounding non-malignant cells unharmed Here, an engineered respiratory syncytial virus (RSV), with the NS1 gene deleted (NS1 gene-deficient RSV, ?NS1 RSV), kills prostate cancer cells, but does not affect normal human cells.Type: GrantFiled: June 6, 2011Date of Patent: June 23, 2015Inventors: Weidong Zhang, Lixian Jiang, Calvin Cao
-
Publication number: 20150140067Abstract: The present invention relates to the identification of microRNAs of the miR-148 family that are involved in the pathogenesis of chronic pulmonary diseases. The present invention relates to micro RNA of the miR-148 family selected from miR-148a, miR-148b and miR-152 for use in the diagnosis, prognosis, prevention and/or therapy of a chronic pulmonary disease. The present invention further relates to miR-148 inhibitors, pharmaceutical compositions comprising such inhibitors, their use in preventing and/or treating chronic pulmonary diseases, and methods for preventing and/or treating chronic pulmonary diseases. The present invention further relates to transgenic, non-human mammals and methods for identifying modulators of miR-148 and methods for diagnosis and/or prognosis of chronic pulmonary diseases.Type: ApplicationFiled: May 15, 2013Publication date: May 21, 2015Inventors: Marcus Mall, Raman Agrawal, Martina Muckenthaler
-
Patent number: 9028809Abstract: Embodiments of the present invention generally disclose methods, compositions and uses for generating and expressing enterobacterial-associated peptides. In some embodiments, enterobacterial-associated peptides include, but are not limited to plague-associated peptides. In certain embodiments, methods generally relate to making and using compositions of constructs including, but not limited to, attenuated or modified vaccinia virus vectors expressing enterobacterial-associated peptides. In other embodiments, vaccine compositions are reported of use in a subject.Type: GrantFiled: November 24, 2010Date of Patent: May 12, 2015Assignee: Takeda Vaccines, Inc.Inventors: Dan T. Stinchcomb, Jorge E. Osorio, Timothy D. Powell, Joseph N. Brewoo
-
Patent number: 9029133Abstract: The present invention provides a recombinant virus containing a nucleotide sequence encoding a tumor-therapeutic full-length antibody with human constant regions, and uses thereof. After a nucleotide sequence of a gene encoding a tumor-therapeutic full-length antibody with human constant regions of the light chain and the heavy chain is inserted into the genome of a recombinant virus, the tumor-therapeutic full-length antibody with human constant regions can be efficiently expressed in tumor cells, thereby inhibit the growth and metastasis of tumors.Type: GrantFiled: April 29, 2004Date of Patent: May 12, 2015Inventors: Qijun Qian, Qi Zhang, Qin Yang, Mengchao Wu
-
Publication number: 20150125923Abstract: The present invention generally relates to compositions and methods of delivering substances in a dry mode, wherein the compositions include a surface layer disposed on the outer surface of the composition that is permeable to carbon dioxide and oxygen. The compositions may be used to deliver microorganisms to remove contaminates, such as oil, chemical, waste, or sewage, from soil, water, or air. In other embodiments, the compositions can also be used for delivering liquid food, liquid food additives, liquid biotech agricultural ingredients, conventional liquid agricultural ingredients, liquid human wellness and dietary supplements, and liquid fragrances and beauty products.Type: ApplicationFiled: October 5, 2011Publication date: May 7, 2015Applicant: DryLet LLCInventors: Ramiro Trevino, Steven R. Ellis
-
Patent number: 9024001Abstract: Provided herein are modified, functional 5? amplification sequences that are defective packaging signals. Also provided are compositions and methods comprising these modified 5? amplification sequences.Type: GrantFiled: May 20, 2005Date of Patent: May 5, 2015Assignee: Novartis Vaccines and Diagnostics, Inc.Inventors: Zequn Tang, Silvia Perri, John Polo
-
Publication number: 20150118189Abstract: The invention relates to the field of microbiology, specifically to a combination of a source of a first enzymatic active domain and a source of a second enzymatic active domain and to a composition comprising said combination. The invention further relates to a composition comprising said combination for use as a medicament, to the use of said composition as an antimicrobial agent and to a method for controlling microbial contamination in a food- or feed product, on and/or in food- or feed processing equipment, on and/or in food- or feed containers.Type: ApplicationFiled: May 7, 2013Publication date: April 30, 2015Applicant: MICREOS HUMAN HEALTH B.V.Inventors: Martin Johannes Loessner, Fritz Eichenseher
-
Publication number: 20150110746Abstract: The present invention relates to compositions and pharmaceutical compositions comprising poxviruses and more particularly extracellular enveloped viruses. The present invention also relates to a process for producing poxviruses and poxviruses obtained thereof. Moreover, the present invention also relates to the use of said poxvirus and said composition for the preparation of a medicament.Type: ApplicationFiled: December 23, 2014Publication date: April 23, 2015Inventors: Daniel Malarme, Yves Cordier, Claude Sene
-
Publication number: 20150110745Abstract: The invention relates to a filamentous bacteriophage, carrying bacterial Lipopolysaccharide (LPS) endotoxin on its surface, for use in treating cancer and in inhibiting angiogenesis, and in a different context, for use in promoting angiogenesis in diseases or conditions in which there is insufficient angiogenesis.Type: ApplicationFiled: March 15, 2013Publication date: April 23, 2015Inventors: Beka Solomon, Eyal Dor-On
-
Publication number: 20150098990Abstract: The present invention concerns methods and compositions that employ peptides that target dorsal root ganglion (DRG) neurons. In particular, the peptides are used to target therapeutic agents, such as proteins, liposomes, or viral particles comprising therapeutic polynucleotides, to one or more peripheral neuropathies or neuropathic pain, for example. In particular cases, the peripheral neuropathies or neuropathic pain is caused directly or indirectly by DRG neuronopathy.Type: ApplicationFiled: October 8, 2014Publication date: April 9, 2015Inventors: Lawrence Chan, Hideto Kojima, Tomoya Terashima
-
Publication number: 20150098928Abstract: Disclosed are compounds of Formula 1, including all geometric and stereoisomers, N-oxides, and salts thereof, wherein A is a 6-membered aromatic ring containing carbon atoms and 0-3 nitrogen atoms as ring members, said ring optionally substituted with 1-5 substituents independently selected from R2; R1 is C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, C4-C7 alkylcycloalkyl or C4-C7 cycloalkylalkyl, each optionally substituted with one or more substituents independently selected from R21; R21 is independently H, halogen, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, C1-C6 alkylthio, C1-C6 haloalkylthio, C1-C6 alkylsulfinyl, C1-C6 haloalkylsulfinyl, C1-C6 alkylsulfonyl, C1-C6 haloalkylsulfonyl, CN or NO2; and Q is as defined in the disclosure.Type: ApplicationFiled: January 6, 2014Publication date: April 9, 2015Applicant: E.I. du Pont de Nemours and CompanyInventors: George Philip Lahm, Ty Wagerle, Ming Xu
-
Patent number: 8999317Abstract: Disclosed are methods and compositions related to the structure and function of APOBEC3G.Type: GrantFiled: November 1, 2007Date of Patent: April 7, 2015Assignee: University of RochesterInventors: Harold C. Smith, Joseph E. Wedekind, Ryan Patrick Bennett
-
Publication number: 20150086581Abstract: Methods of diagnosing and treating patients afflicted with acne, including diagnosing one as having acne if the individual possesses RT4, RT5, RT7, RT8, RT9, or RT10. Methods for treating acne include administering an effective amount of a drug specifically targeting RT4, RT5, RT7, RT8, RT9, or RT10, such as small molecules, antisense molecules, siRNAs, biologics, antibodies, phages, vaccines, or combination thereof.Type: ApplicationFiled: March 15, 2013Publication date: March 26, 2015Inventors: Huiying Li, Shuta Tomida
-
Publication number: 20150086605Abstract: The technology described herein is directed to compositions comprising at least a first porous biomaterial layer and a second impermeable biomaterial layer and methods relating thereto. In some embodiments, the compositions and methods described herein relate to wound healing, e.g. repair of wounds and/or tissue defects.Type: ApplicationFiled: February 5, 2013Publication date: March 26, 2015Inventors: Joshua R. Mauney, Carlos R. Estrada, David L. Kaplan, Eun Seok Gil
-
Patent number: 8980282Abstract: Herpes Simplex Viruses are disclosed having single-chain antibodies (scFv) embedded in the viral envelope via fusion with glycoprotein D and with glycoprotein H and L.Type: GrantFiled: April 2, 2008Date of Patent: March 17, 2015Assignee: Virttu Biologics LimitedInventor: Joe Conner
-
Patent number: 8981073Abstract: Disclosed are an HCV gene having higher replication efficiency and higher reinfection efficiency than the known HCV gene of genotype 1b, an RNA replicon having this gene, a cell infected with this RNA replicon, which cell allows replication of HCV, and an HCV particle. The hepatitis C virus gene encodes an amino acid sequence wherein the 979th amino acid is threonine; the 1804th amino acid is leucine; and the 1966th amino acid is lysine. An HCV gene which can propagate in vitro and has higher replication efficiency and higher reinfection efficiency than the known HCV gene of genotype 1b was provided.Type: GrantFiled: October 7, 2011Date of Patent: March 17, 2015Assignee: Advanced Life Science Institute, Inc.Inventors: Kenichi Mori, Noboru Maki, Hiromi Fukai
-
Patent number: 8957012Abstract: This invention relates to methods and compositions for the treatment of malignancies associated with gamma-herpesvirus infection. Specifically, the invention relates to the use of gamma-secretase inhibitors to prevent the production of intracellular Notch1 thereby arresting the growth of the infected cells.Type: GrantFiled: January 24, 2012Date of Patent: February 17, 2015Assignee: The Trustees of the University of PennsylvaniaInventors: Erle S. Robertson, Ke Lan
-
Publication number: 20150044280Abstract: The invention provides methods of reducing or decreasing a size of a tumor or eliminating a tumor or inhibiting, decreasing, or reducing neo-vascularization or angiogenesis in a tumor in a patient by administering an adenovirus comprising a nucleic acid construct comprising a FAS-chimera gene operably linked to an endothelial cell-specific promoter. Also provided is a homogeneous population of an adenovirus comprising a FAS-chimera gene operably linked to an endothelial cell-specific promoter and its uses thereof.Type: ApplicationFiled: October 29, 2014Publication date: February 12, 2015Applicant: Vascular Biogenics Ltd.Inventors: Eyal BREITBART, Andrea Leubitz, Erez Feige, Richard Penson
-
Publication number: 20150044175Abstract: Disclosed herein are purified bacteriophage preparations that effectively lyse a plurality of C. perfringens strains. In one embodiment, a purified bacteriophage preparation includes four or more C. perfringens-specific bacteriophage, wherein each bacteriophage has lytic activity against at least five Clostridium species strains. In another embodiment, the purified bacteriophage preparation includes five or more C. perfringens-specific bacteriophage.Type: ApplicationFiled: September 2, 2014Publication date: February 12, 2015Inventors: Jeremy Mathers, Alexander Sulakvelidze
-
Publication number: 20150038329Abstract: Disclosed are compounds of Formula 1, wherein R1 is phenyl or pyridinyl, each optionally substituted with Q and up to 3 substituents independently selected from R2; each R2 is independently halogen, cyano, SF5, C1-C4 alkyl, C1-C4 haloalkyl, C1-C4 alkoxy, C1-C4 haloalkoxy, C1-C4 alkylthio or C1-C4 haloalkylthio; and Q is phenyl or pyridinyl, each optionally substituted with up to 5 substituents independently selected from the group consisting of halogen, cyano, C1-C4 alkyl, C1-C4 haloalkyl, C1-C4 alkoxy and C1-C4 haloalkoxy. Also disclosed are compositions containing the compounds of Formula 1 and methods for controlling an invertebrate pest comprising contacting the invertebrate pest or its environment with a biologically effective amount of a compound or a composition of the invention.Type: ApplicationFiled: October 22, 2014Publication date: February 5, 2015Inventor: THOMAS FRANCIS PAHUTSKI, JR.
-
Publication number: 20150037288Abstract: Methods of using viruses labeled with alkyne-modified biomolecules, such as fatty acids, carbohydrates and lipids, to treat a plant, an insect or an animal infected with a virus or to increase the infectivity of a virus, such as the human immunodeficiency virus, are provided. Also provided are methods of labeling a virus, such as human immunodeficiency virus, with an alkyne-modified biomolecule, such as a fatty acid, a carbohydrate, or an isoprenoid lipid. The viruses labeled with alkyne-modified biomolecules may be combined with a pharmaceutically acceptable excipient to produce a pharmaceutical composition, optionally containing another anti-viral agent and/or a delivery agent, such as a liposome.Type: ApplicationFiled: January 25, 2013Publication date: February 5, 2015Inventors: Brian Agnew, David Graham
-
Publication number: 20150037287Abstract: There is a disclosed a method of killing abnormal cells such as malignant cells including melanoma cells, using a virus recognising at least one of a cell adhesion molecule and a complement regulatory protein. The virus may be a member of the Picornaviridae family. Coxsackie A-group viruses have been found to be particularly suitable. The cell adhesion molecule is desirably a member of the immunoglobulin (Ig) superfamily. Typically, the complement regulatory protein will be DAF.Type: ApplicationFiled: March 31, 2014Publication date: February 5, 2015Applicant: Viralytics LimitedInventor: Darren R. Shafren
-
Publication number: 20150030629Abstract: The present invention relates to methods for producing dried formulations of biopharmaceutical agents that aim to minimize the loss of activity of the agents upon drying and to provide dried formulations with an extended shelf life. The method comprises the step of drying an aqueous solution comprising, in addition to the biopharmaceutical agent, at least an amino acid, a polyol and a metal salt. Preferably the amino acid is glutamate, the polyol is sorbitol and optionally also mannitol and the metal salt is a magnesium salt. The solution is dried by vacuum drying or by lyophilization. The methods are particularly useful for preparing dried formulations of viruses such as poliovirus or respiratory syncytial virus to be used for vaccination. The invention also relates to dried formulations prepared in accordance with the methods of the invention and to their use as medicaments, e.g. as vaccines.Type: ApplicationFiled: March 5, 2013Publication date: January 29, 2015Applicants: en SportInventors: Heleen Kraan, Jean-Pierre Amorij
-
Publication number: 20150030567Abstract: Described is a pharmaceutical composition comprising (a) a parvovirus and (b) a histone deacetylase inhibitor (HDACI) and the use of said composition for treatment of cancer, e.g., brain tumor, cervical carcinoma, or pancreatic carcinoma.Type: ApplicationFiled: October 6, 2014Publication date: January 29, 2015Inventors: Antonio MARCHINI, Jean ROMMELAERE, Nazim EL-ANDALOUSSI, Georgi HRISTOV, Junwei LI
-
Publication number: 20150030565Abstract: The present invention provides a method to prepare purified enveloped (e.g., flavivirus) viral particle preparations employing ion exchange chromatography and tangential flow filtration.Type: ApplicationFiled: January 8, 2013Publication date: January 29, 2015Applicant: Sanofi Pasteur Biologics, LLCInventors: Sophia Mundle, Stephen Anderson
-
Patent number: 8940291Abstract: Provided are viral sensitizing compounds that enhance the efficacy of viruses by increasing spread of the virus in cells, increasing the titer of virus in cells, or increasing the cytotoxicity of virus to cells. Other uses, compositions and methods of using same are also provided.Type: GrantFiled: July 7, 2010Date of Patent: January 27, 2015Assignee: Ottawa Hospital Research InstituteInventors: John Bell, Jean-Simon Diallo, Fabrice Le Boeuf
-
Patent number: 8932580Abstract: The present invention relates to a method for the selective purification of bacterial cells and/or cell components, whereby the purification is performed by means of a solid support.Type: GrantFiled: July 28, 2009Date of Patent: January 13, 2015Assignees: Hyglos Invest GmbH, Biomerieux S.A.Inventors: Michael Schutz, Renate Grassl, Roman Meyer, Sibylle Frick, Ingrid Robl, Thomas Zander, Stefan Miller
-
Patent number: 8932604Abstract: Recombinant multivalent non-pathogenic Marek's Disease virus constructs that encode and express both Infectious Laryngotracheitis Virus and Newcastle Disease virus protein antigens, and methods of their use in poultry vaccines.Type: GrantFiled: October 19, 2012Date of Patent: January 13, 2015Assignee: Intervet Inc.Inventors: Stephanie Cook, Mohamad Morsey, Gary Petersen, Paulus Jacobus Antonius Sondermeijer
-
Publication number: 20150011389Abstract: The present invention relates to active compound combinations for reducing the damage of plants and plant parts as well as losses in harvested fruits or vegetables caused by insects, nematodes or phytopathogens and which have fungicidal or nematicidal or insecticidal activity including any combination of the three activities, in particular within a composition, which comprises (A) Fluopyram and (B) one biological control agent, in particular bacteria, fungi or yeasts, protozoa, viruses, entomopathogenic nematodes, inoculants, botanicals and products produced by microorganisms including proteins or secondary metabolites. Moreover, the invention relates to a method for curatively or preventively controlling insects, nematodes or phytopathogens on the plant, plant parts, harvested fruits or vegetables, to the use of a combination according to the invention for the treatment of seed, to a method for protecting a seed and not at least to the treated seed.Type: ApplicationFiled: January 22, 2013Publication date: January 8, 2015Inventor: Elke Hellwege
-
Patent number: 8926946Abstract: A system for targeted delivery of agents (e.g., molecular probes, diagnostic agents, therapeutic agents, imaging agents, research or analytical compounds, enzymes, peptides, proteins, lipids, lipoproteins, sugars, hormones, vitamins, nucleic acids, viruses, bacteria, and/or cells) including use of a composition containing the agent and a targeting moiety, specific for a determinant at the target location. An exemplary composition of the system includes a targeting moiety of one of peptides ?3, 2?3, 3?3, A1, B7, B8, B9, B1O, and D6, specific for targeting ICAM-I. The system enables effective, versatile, and safe targeting and transport of agents. The system is useful in research applications, as well as in the context of translational science and clinical interventions.Type: GrantFiled: June 4, 2010Date of Patent: January 6, 2015Assignee: University of Maryland, College ParkInventors: Silvia Muro Galindo, Ming Meng, Carmen Garnacho Montero